Conference LibraryGated
Claim · in vivo BCMA CAR-T feasibility demonstrated in 9 r/r MM patients
9 / 9 r/r multiple myeloma patients on ESO-T01 in vivo BCMA CAR-T phase 1 successfully generated CAR-T cells in vivo · CAR-T cell levels similar to ex vivo delivery · extramedullary lesion elimination signal · 3-4 month follow-up (insufficient for late-stage outcome claim).
- Type
- claim
- Domain
- car-t
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- Provenance
- m622_intel_seed_2026-05-16
- evidence_grade
- A
- category
- clinical_feasibility_claim
- status
- verified
- instance_tag
- sunvax-antibody-2025
- clinical_claim_softening
- "feasibility demonstration · 3-4 month follow-up insufficient · NOT validated late-stage clinical model"
- claim_statement
- 9 / 9 r/r multiple myeloma patients on ESO-T01 in vivo BCMA CAR-T phase 1 successfully generated CAR-T cells in vivo · CAR-T cell levels similar to ex vivo delivery · extramedullary lesion elimination signal · 3-4 month follow-up (insufficient for late-stage outcome claim).
- claim_evidence_grade
- A
- supporting_papers
- m622-b5-paper-naturemed-esot01-001,m622-b5-paper-lancet-esot01-001
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.